{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:28:05Z","timestamp":1785583685189,"version":"3.56.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"DOI":"10.7759\/cureus.83764","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:44:25Z","timestamp":1746773065000},"source":"Crossref","is-referenced-by-count":2,"title":["Intraocular Inflammation Following Faricimab Intravitreal Injection Treated With Sub-tenon Triamcinolone Acetonide Injection"],"prefix":"10.7759","author":[{"given":"Shinnosuke","family":"Yasuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tsujinaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2641","article-title":"Diabetic retinopathy: a position statement by the American Diabetes Association","volume":"40","author":"Solomon SD","year":"2017","unstructured":"Solomon SD, Chew E, Duh EJ, et al.. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care. 2017, 40:412-18. 10.2337\/dc16-2641","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara N","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016, 15:385-403. 10.1038\/nrd.2015.17","journal-title":"Nat Rev Drug Discov"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial frowth factor - a with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni J","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, et al.. Simultaneous inhibition of angiopoietin-2 and vascular endothelial frowth factor - a with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019, 126:1155-70. 10.1016\/j.ophtha.2019.03.023","journal-title":"Ophthalmology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2293925","article-title":"Uveitis following intravitreal injections of faricimab: a case report","volume":"32","author":"Palmieri F","year":"2024","unstructured":"Palmieri F, Younis S, Bedan Hamoud A, Fabozzi L. Uveitis following intravitreal injections of faricimab: a case report. Ocul Immunol Inflamm. 2024, 32:1873-7. 10.1080\/09273948.2023.2293925","journal-title":"Ocul Immunol Inflamm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.0530","article-title":"Severe intraocular inflammation following intravitreal faricimab","volume":"142","author":"Thangamathesvaran L","year":"2024","unstructured":"Thangamathesvaran L, Kong J, Bressler SB, et al.. Severe intraocular inflammation following intravitreal faricimab. JAMA Ophthalmol. 2024, 142:365-70. 10.1001\/jamaophthalmol.2024.0530","journal-title":"JAMA Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.08.008","article-title":"Severe intraocular inflammation after intravitreal injection of faricimab: a single-site case series of six patients","volume":"269","author":"Ben Ghezala I","year":"2025","unstructured":"Ben Ghezala I, Gabrielle PH, Sibert M, Steinberg LA, Dautriche A, Arnould L, Creuzot-Garcher C. Severe intraocular inflammation after intravitreal injection of faricimab: a single-site case series of six patients. Am J Ophthalmol. 2025, 269:11-19. 10.1016\/j.ajo.2024.08.008","journal-title":"Am J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and Lucerne: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani AM","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, et al.. TENAYA and Lucerne: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024, 131:914-26. 10.1016\/j.ophtha.2024.02.014","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong TY","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, et al.. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024, 131:708-23. 10.1016\/j.ophtha.2023.12.026","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/11206721241306225","article-title":"Acute intra ocular inflammation following intravitreal injections of faricimab: a multicentric case series","author":"Le HM","year":"2024","unstructured":"Le HM, Querques G, Guenoun S, et al.. Acute intra ocular inflammation following intravitreal injections of faricimab: a multicentric case series. Eur J Ophthalmol. 2024, 11206721241306225. 10.1177\/11206721241306225","journal-title":"Eur J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-06736-6","article-title":"Vitritis following intravitreal faricimab: a retrospective monocentric analysis","author":"Bourdin A","year":"2025","unstructured":"Bourdin A, Cohen SY, Nghiem-Buffet S, Smadja J, Paques M, Fajnkuchen F, Mrejen S. Vitritis following intravitreal faricimab: a retrospective monocentric analysis. Graefes Arch Clin Exp Ophthalmol. 2025, 10.1007\/s00417-025-06736-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.02.033","article-title":"Faricimab-associated intraocular inflammation with features of herpes simplex virus","volume":"273","author":"Janmohamed IK","year":"2025","unstructured":"Janmohamed IK, Salam MA, Jamall O, et al.. Faricimab-associated intraocular inflammation with features of herpes simplex virus. Am J Ophthalmol. 2025, 273:212-20. 10.1016\/j.ajo.2025.02.033","journal-title":"Am J Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100680","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug SJ","year":"2020","unstructured":"Haug SJ, Hien DL, Uludag G, et al.. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020, 18:100680. 10.1016\/j.ajoc.2020.100680","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100687","article-title":"Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations","volume":"18","author":"Jain A","year":"2020","unstructured":"Jain A, Chea S, Matsumiya W, et al.. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020, 18:100687. 10.1016\/j.ajoc.2020.100687","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal CR","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L, et al.. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020, 127:1345-59. 10.1016\/j.ophtha.2020.04.017","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s J","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, et al.. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021, 128:1050-9. 10.1016\/j.ophtha.2020.11.011","journal-title":"Ophthalmology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/358133-intraocular-inflammation-following-faricimab-intravitreal-injection-treated-with-sub-tenon-triamcinolone-acetonide-injection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:44:26Z","timestamp":1746773066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/358133-intraocular-inflammation-following-faricimab-intravitreal-injection-treated-with-sub-tenon-triamcinolone-acetonide-injection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.83764","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,8]]}}}